Journals / Viral Hepatitis Journal / 2018 / Cilt: 24 - Sayı: 1

Should Hepatitis C Virus Antibody Be Used for Screening Purposes?

Hepatit C Virüs Antikoru Tarama Amacıyla Kullanılmalı Mı?

Pages
18–20
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nine of 23980 samples, whichwere screened for preoperative preparation, had reactive HCV RNA.One hundred thirty seven of 4101 samples, which were obtained fordiagnostic purposes in the gastroenterology and infectious diseasesclinics, were HCV RNA positive.Conclusion: Positive results should be confirmed with HCV RNAtesting; if possible, testing for HCV antibodies with other methods,before HCV RNA testing, will decrease the number of tests usingmolecular methods; and screening for HCV antibodies is not costeffectiveespecially in populations with a low prevalence of HCVantibody positivity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, hepatitis C virus (HCV) RNA results wereretrospectively investigated in patients with reactive HCV antibodies.Materials and Methods: HCV antibody test was performedELISA method.
📊
Key Findings & Data:The quantitative HCV RNA test was carried out byAmpliPrep/COBAS TaqMan HCV test.Results: HCV antibody reactivity was detected in 358 of 28081samples, 255 samples collected from 358 anti-HCV positivepatientsand were tested for HCV RNA were included in the study.The detected HCV RNA positivity rate was 5.8% in patients whohad low titer reactive HCV antibody and 76.3% in patients, whohad high titer reactive HCV antibody.
💡
Conclusion & Impact:Nine of 23980 samples, whichwere screened for preoperative preparation, had reactive HCV RNA.One hundred thirty seven of 4101 samples, which were obtained fordiagnostic purposes in the gastroenterology and infectious diseasesclinics, were HCV RNA positive.Conclusion: Positive results should be confirmed with HCV RNAtesting; if possible, testing for HCV antibodies with other methods,before HCV RNA testing, will decrease the number of tests usingmolecular methods; and screening for HCV antibodies is not costeffectiveespecially in populations with a low prevalence of HCVantibody positivity.
🔬Design:Research Article
📍Scope:28081samples
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, hepatitis C virus (HCV) RNA results wereretrospectively investigated in patients with reactive HCV antibodies.Materials and Methods: HCV antibody test was performedELISA method. Enzyme linked fluorescence assay was used as adifferent method. The quantitative HCV RNA test was carried out byAmpliPrep/COBAS TaqMan HCV test.Results: HCV antibody reactivity was detected in 358 of 28081samples, 255 samples collected from 358 anti-HCV positivepatientsand were tested for HCV RNA were included in the study.The detected HCV RNA positivity rate was 5.8% in patients whohad low titer reactive HCV antibody and 76.3% in patients, whohad high titer reactive HCV antibody. Nine of 23980 samples, whichwere screened for preoperative preparation, had reactive HCV RNA.One hundred thirty seven of 4101 samples, which were obtained fordiagnostic purposes in the gastroenterology and infectious diseasesclinics, were HCV RNA positive.Conclusion: Positive results should be confirmed with HCV RNAtesting; if possible, testing for HCV antibodies with other methods,before HCV RNA testing, will decrease the number of tests usingmolecular methods; and screening for HCV antibodies is not costeffectiveespecially in populations with a low prevalence of HCVantibody positivity.

Özet

Amaç: Bu çalışmada, reaktif hepatit C virüsü (HCV) antikorları olan hastalarda HCV RNA sonuçları retrospektif olarak incelendi. Gereç ve Yöntemler: HCV antikor testi ELISA yöntemi ile çalışıldı. Enzim Bağlantılı Floresans testi farklı bir yöntem olarak kullanılmıştır. Kantitatif HCV RNA testi AmpliPrep/COBAS TaqMan HCV testi ile gerçekleştirildi. Bulgular: HCV antikoru için toplam 28081 numunenin 358’inde reaktivite tespit edildi. Çalışmaya anti-HCV antikoru pozitif 358 hastadan HCV RNA çalışılan 255 hasta örneği dahil edildi. Düşük titrede reaktif HCV antikoru olan hastalarda %5,8 ve yüksek titrede reaktif HCV antikoru olan hastalarda %76,3 HCV RNA pozitifliği saptandı. Preoperatif hazırlık kapsamında test edilen 23980 örneğin 9’unda HCV RNA pozitifti. Gastroenteroloji ve enfeksiyon hastalıkları kliniklerinden tanı amaçlı olarak gelen 4101 örneğinin 137’sinde HCV RNA pozitif idi. Sonuç: Pozitif sonuçlar HCV RNA ile doğrulanmalıdır, eğer imkan varsa HCV RNA bakılmadan önce farklı bir yöntemle HCV antikoru çalışılmasının moleküler yöntemle çalışılacak test sayısını azaltacağı ve tarama amaçlı HCV antikoru bakılmasının özellikle düşük prevalanslı toplumlarda maliyet etkin olmadığı görüşüne varılmıştır.

🔖

Cite This Article

TOPKAYA, A. E., ŞAFAK, B., TOMBAK, Ö. (2022). Should Hepatitis C Virus Antibody Be Used for Screening Purposes?. Viral Hepatitis Journal, Cilt: 24 - Sayı: 1, 18–20. https://ajindex.com/articles/646390

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. WHO Hepatitis C Fact sheet, updated October 2017. http:// www.who.int/mediacentre/factsheets/fs164/en/ (accessed 30 November 2017). Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, updated version april 2016. http:// www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/ en/ (accessed 13 December 2017).
  2. Aygen B, Demirtürk N, Türker N, Asan A, Eraksoy H, Gürbüz Y, İnan D, Keten D, Koçulu S, Öncü S, Özkaya D, Saltoğlu N, Sayan M, Süer K, Şener A, Tekin S, Tuna N, Yazıcı S. Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update. Klimik Dergisi. 2017;30(Özel Sayı 1):2-36. Centers for Disease Control and Prevention (CDC). Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62:362-365.
  3. Zer Y, Karaoğlan İ, Çiçek H, Karagöz ID, Sağlam M. Evaluation of the patients with low levels of anti-HCV positivity. Mikrobiyol Bul. 2009;43:133-139.
  4. Köse Ş, Ece G, Şamlıoğlu P, Topaloğlu S. Evaluation of HCV RNA levels in samples with low anti-hepatitis C virus antibodies at Tepecik Education and Research Hospital. Turk Hij Den Biyol Derg. 2011;68:191-196. TC Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Bulaşıcı Hastalıkların Laboratuvar T anısı için Saha Rehberi. Ankara: Kolektif. 2014.
  5. Wu S, Liu Y, Cheng L, Yin B, Peng J, Sun Z. Clinical evaluation of the signal-to-cutoff ratios of hepatitis C virus antibody screening tests used in China. J Med Virol. 2011;83:1930-1937.
  6. Ecemiş T, Akçalı S, Erbay Dündar P, Şanlıdağ T. The threshold value of Anti-HCV test in the diagnosis of HCV infection. Turkiye Klinikleri J Med Sci. 2012;32:1648-1652.
  7. Vermehren J, Schlosser B, Domke D, Elanjimattom S, Müller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N, Walcher F, Möckel M, Lehmann R, Zeuzem S, Sarrazin C, Berg T. High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. PLoS One. 2012;7:e41206. Tolmane I, Rozentale B, Keiss J, Arsa F, Brigis G, Zvaigzne A. The prevalence of viral hepatitis C in Latvia: a population-based study. Medicina (Kaunas). 2011;47:532-535.
  8. Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birt